
Setomimycin

®

MedChemExpress

Cat. No.:	HY-124439	Q
CAS No.:	69431-87-4	
Molecular Formula:	C ₃₄ H ₂₈ O ₉	
Molecular Weight:	580.58	но́ (
Target:	Antibiotic; Bacterial; SARS-CoV	
Pathway:	Anti-infection	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	OH



Product Data Sheet

BIOLOGICAL ACTIVITY						
Description	Setomimycin is a potent antibiotic. Setomimycin inhibits the SARS-CoV-2 Mpro enzyme with an IC ₅₀ value of 12.02 μM. Setomimycin shows anti-inflammatory and antioxidant properties. Setomimycin shows antiproliferative and antitumor activity ^{[1][2]} .					
IC ₅₀ & Target	et IC ₅₀ : 12.02 μM (SARS-CoV-2 Mpro) ^[1]					
In Vitro	Setomimycin (0.01-1 μM) inhibits the release of cytokines IL-1β, IL-6 and TNF-α and nitric oxide release from LPS stimulated RAW 264.7 cells in a dose-dependent manner ^[1] . Setomimycin (compound 1) shows antimicrobial activity with MICs of 8, 4, 16, 4 μg/mL for Staphylococcus aureus, Bacillus cereus, Bacillus subtilis, Micrococcus luteus, respectively ^[2] . Setomimycin (0-100 μM; 5 days) shows antiproliferative activity and inhibits colony formation ^[2] . Setomimycin (4, 5.5, 7 μM) decreases the protein expression of p-MEK, p-ERK, Bcl-2, increases the expression of Par-4 ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay ^[2]					
	Cell Line:	A549; HOP-92; Panc-1; MiaPaca-2 cells				
	Concentration:	0-100 μΜ				
	Incubation Time:	44 h				
	Result:	Showed antiproliferative activity with IC ₅₀ s of 11.45, >100, 48, 4.57 μM for A549; HOP-92; Panc-1; MiaPaca-2 cells, respectively.				
	Western Blot Analysis ^[2]					
	Cell Line:	MCF-7, HCT-116 cells				
	Concentration:	4, 5.5, 7 μM				
	Incubation Time:					
	Result:	Decreased the protein expression of p-MEK, p-ERK, Bcl-2, increased the expression of Par-4 in a dose-dependent manner.				

In Vivo

Setomimycin (20 mg/kg; i.p.; alternate days for two weeks) shows antitumor activity in mice^[2]. Pharmacokinetic Parameters of Setomimycin in female BALB/c mice^[2].

Pharmacokinetic parameters	Value
C _{max} (ng/ml)	694 ± 62
T _{max} (h)	0.3 ± 0.1
T _{1/2} (h)	2.3 ± 0.5
AUC _{0-t} (ng.h/mL)	2613 ± 111
AUC _{0-α} (ng.h/mL)	2734 ± 108
V _d (L/Kg)	24 ± 4
Cl (L/h/Kg)	7.4 ± 0.3

Female BALB/c mice, 20 mg/kg ip (1 % DMSO +30 % PEG-200 + 2 % Tween 80 + q.s. water (v/v))^[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6 weeks, 25-30 g, female BALB/c mice (4T1 cells) ^[2]
Dosage:	20 mg/kg
Administration:	I.p.; every other day for two weeks
Result:	Decreased primary tumor weight (76%) and volume (90.5%).

REFERENCES

[1]. Manhas RS, et al. Setomimycin as a potential molecule for COVID19 target: in silico approach and in vitro validation. Mol Divers. 2023 Apr;27(2):619-633.

[2]. Manhas RS, et al. Isolation and anticancer activity evaluation of rare Bisaryl anthraquinone antibiotics from novel Streptomyces sp. strain of NW Himalayan region. Chem Biol Interact. 2022 Sep 25;365:110093.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898Fax: 609-228-5909E-mail: tech@MedChemExpress.comAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA